Conditions: Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Keywords: Medullary Thyroid Carcinoma Medullary Thyroid Cancer Vandetanib
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 14
Healthy volunteers: no

Brief summary:
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.

Detailed description:
A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma

Arms:
arm 1: 300 mg/day vandetanib

Interventions: intervention 1: Vandetanib 300mg
Intervention descriptions: intervention 1: 300 mg oral dose once daily (100 mg x 3 tablets)

Protocol document: